Cellectar Biosciences today announced the effective prices of $1.15 per share of common stock and one-half of a Series H Warrant of an underwritten public offering to raise approximately $20 million.

According to a release, this includes the full exercise of the underwriters’ over-allotment option to purchase additional shares of common stock and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Investors will receive a five-year warrant exercisable for each share of the company’s Series H warrants purchased.